A study titled “Patients’ perspectives on the challenges associated with receiving non-oral pulmonary arterial hypertension treatment: a mixed methods study”, by Aldo Aguirre-Camacho, was published on “Therapeutic Advances in Respiratory Disease” on November 21, 2024. The study investigates how non-oral treatments for pulmonary arterial hypertension impact patients’ quality of life beyond the challenges posed by the disease itself. It uses a mixed-methods approach, combining surveys from 83 patients with interviews and group discussions involving nine patients.
Key findings
1. Symptomatology and Functional Disability: No significant differences were observed between patients on oral-only vs. non-oral therapies.
2. Quality of Life: Patients on non-oral therapies reported poorer quality of life after accounting for factors like age, symptoms, functional disability, psychological well-being and stress.
3. Patient Experiences: While non-oral therapies improved health status, they caused significant apprehension, disrupted daily activities and created self-management challenges, negatively affecting subjective well-being.
Conclusion
The study concludes that non-oral therapy regimens may add a unique burden to pulmonary arterial hypertension patients’ quality of life, highlighting the need for supportive strategies to address these challenges.
Read more at this link on the Sage Journals web page
Citation
Aguirre-Camacho A. Patients’ perspectives on the challenges associated with receiving non-oral pulmonary arterial hypertension treatment: a mixed methods study. Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241289807. doi: 10.1177/17534666241289807. PMID: 39569502; PMCID: PMC11580095.
Many thanks for Deger Kesimoglu for writing this summary for us.
